AMCP Annual

Soumya Vishwanath, PharmD, senior manager of Formulary Strategy at Magellan Rx Management, talked about digital therapeutics in the behavioral health space and formulary strategy space during the annual AMCP 2022 conference in Chicago.

AllianceRx Walgreens Prime study has found that patients taking Ocaliva may not be adherent to their treatment regimen for rare liver disease.

“Popping a pill” makes cancer treatment more convenient, but research presented at the AMCP annual meetings shows that almost half of cancer patients on oral therapies are nonadherent. Oral administration typically moves a drug to the pharmacy benefit, which can mean high out-of-pocket costs and, in turn, nonadherence.

A disconnect exists between payers and patients with rare diseases about including patient input in the formulary process for orphan drugs.

Over 130 digital therapeutics for behavioral health are in the pipeline, but many payers are still sussing out how best to evaluate them and perhaps provide coverage, according to panelists at AMCP 2022. And for all of their advantages, digital therapeutics have some notable limitations and drawbacks.

Michael Ciarametaro, MBA, National Pharmaceutical Council National discusses gene therapy and the Medicaid Best Price Rule with MHE during the annual AMCP conference in Chicago.

Three thousand people are expected to attend the four-day meeting in Chicago. Kali Cyrus, an assistant professor at Johns Hopkins who identifies as Black, female and queer, is leading a session tomorrow on bias.

AmerisourceBergen/Xcenda survey finds payers believe biosimilars provide costs savings, and they are expected to continuing contracting with manufacturers.

Most of the solutions have established systems to track patient outcomes over time, and several include performance guarantees as part of their solution.